Two-component spike nanoparticle vaccine protects macaques from SARS-CoV-2 infection

Philip J. M. Brouwer, Mitch Brinkkemper, Pauline Maisonnasse, Nathalie Dereuddre-Bosquet, Marloes Grobben, Mathieu Claireaux, Marlon de Gast, Romain Marlin, Virginie Chesnais, S. golène Diry, Joel D. Allen, Yasunori Watanabe, Julia M. Giezen, Gius Kerster, Hannah L. Turner, Karlijn van der Straten, Cynthia A. van der Linden, Yoann Aldon, Thibaut Naninck, Ilja BontjerJudith A. Burger, Meliawati Poniman, Anna Z. Mykytyn, Nisreen M. A. Okba, Edith E. Schermer, Marielle J. van Breemen, Rashmi Ravichandran, Tom G. Caniels, Jelle van Schooten, Nidhal Kahlaoui, Vanessa Contreras, Julien Lemaître, Catherine Chapon, Raphaël Ho Tsong Fang, Julien Villaudy, Kwinten Sliepen, Yme U. van der Velden, Bart L. Haagmans, Godelieve J. de Bree, Eric Ginoux, Andrew B. Ward, Max Crispin, Neil P. King, Sylvie van der Werf, Marit J. van Gils, Roger le Grand, Rogier W. Sanders

Research output: Contribution to journalArticleAcademic

94 Citations (Scopus)


The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic is continuing to disrupt personal lives, global healthcare systems, and economies. Hence, there is an urgent need for a vaccine that prevents viral infection, transmission, and disease. Here, we present a two-component protein-based nanoparticle vaccine that displays multiple copies of the SARS-CoV-2 spike protein. Immunization studies show that this vaccine induces potent neutralizing antibody responses in mice, rabbits, and cynomolgus macaques. The vaccine-induced immunity protects macaques against a high-dose challenge, resulting in strongly reduced viral infection and replication in the upper and lower airways. These nanoparticles are a promising vaccine candidate to curtail the SARS-CoV-2 pandemic. Brouwer et al. present preclinical evidence in support of a COVID-19 vaccine candidate, designed as a self-assembling two-component protein nanoparticle displaying multiple copies of the SARS-CoV-2 spike protein, which induces strong neutralizing antibody responses and protects from high-dose SARS-CoV-2 challenge.

Original languageEnglish
Article number365726
Pages (from-to)1188-1200.e19
Number of pages36
Issue number5
Early online date2021
Publication statusPublished - 4 Mar 2021


  • B cells
  • COVID-19
  • SARS-CoV-2
  • antibodies
  • immunity
  • macaques
  • nanoparticles
  • protection
  • vaccine

Cite this